Contact Information: Company Contact: Delcath Systems, Inc. Richard Taney (212) 489-2100 Investor Relations Contact: Strategic Growth International, Inc. Richard E. Cooper/Cass Almendral (212) 838-1444 Public Relations Contact: Rubenstein Associates, Inc. Robin Wagge (212) 843-8006
Delcath Systems Targeted Drug Delivery Technology to Be Presented at Western Angiographic and Interventional Society Annual Meeting
| Source: Delcath Systems, Inc.
NEW YORK, NY--(Marketwire - September 19, 2008) - Delcath Systems, Inc. (NASDAQ : DCTH ), a
leading developer of regional therapy for cancer, today announced that Dr.
Charles Nutting of Swedish Medical Center in Englewood, Colorado will
deliver a presentation at the 38th Annual Meeting of the Western
Angiographic and Interventional Society ("WAIS"). Dr. Nutting will discuss
his involvement with Delcath's Phase III trial of its Percutaneous Hepatic
Perfusion (PHP) System for the treatment of inoperable metastatic melanoma
at the conference, held in Maui, Hawaii from September 20-25, 2008.
Dr. Nutting, a Principal Investigator on the Phase III trial, will present
Delcath's PHP technology and its role in the treatment of liver metastases.
Dr. Nutting has been at the forefront of regional therapy for the treatment
of cancer, and is a leader in the field of interventional oncologic
techniques. He has recently joined the Delcath trial, as the Principal
Investigator at Swedish Medical Center, one of the nine enrolling centers
for the randomized Phase III trial.
"Dr. Nutting's presentation marks an expansion in awareness for the Delcath
PHP System," stated Richard L. Taney, President and CEO of Delcath. "This
is the first major presentation regarding the Phase III trial by an
Investigator outside of the National Cancer Institute. As the oncology
community becomes more familiar with the potential benefits of Delcath's
PHP technology, this presentation will further the awareness of the
Interventional Radiology Community which will be a key driver in the
adoption of this unique treatment for inoperable cancers."
WAIS is a regional society of leading physicians from the western states
and Canada dedicated to vascular and interventional radiology, and
image-guided techniques for the diagnosis and treatment of cancer and other
illnesses. Information on this organization and conference can be found at
www.westernangio.org.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in
cancer treatment. The Company has developed a proprietary, patented system
which will improve the efficacy of cancer treatment while reducing the
considerable, systemic side-effects of chemotherapy. Delcath's novel drug
delivery platform is capable of delivering anti-cancer drugs at very high
doses to a specific organ or region of the body while preventing these high
doses of drug from entering the patient's bloodstream. The Company is
currently enrolling patients in Phase III and Phase II clinical studies for
the treatment of liver cancers using high doses of melphalan. The Company's
intellectual property portfolio consists of twenty-eight patents on a
worldwide basis including the U.S., Europe, Asia and Canada. For more
information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor
for forward-looking statements made by the Company or on its behalf. This
news release contains forward-looking statements, which are subject to
certain risks and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our ability to
successfully complete Phase III clinical trials and secure regulatory
approval of our current or future drug-delivery system and uncertainties
regarding our ability to obtain financial and other resources for any
research, development and commercialization activities. These factors, and
others, are discussed from time to time in our filings with the Securities
and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made.
We undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after the
date they are made.